Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
The Journal of Pathology
|
May 14, 2008
Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas
P T Simpson, J S Reis-Filho, M B K Lambros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2022
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
P Terraf, F Pareja, D N Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P Selenica, A Marra, N J Choudhury, et al.
The Journal of Pathology
|
June 2, 2006
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
J S Reis-Filho, C Pinheiro, M B K Lambros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
J Veeraraghavan, C De Angelis, R Mao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2013
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
A F C Okines, D Gonzalez de Castro, D Cunningham, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
The Journal of Pathology
|
May 14, 2008
Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas
P T Simpson, J S Reis-Filho, M B K Lambros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 25, 2022
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
P Terraf, F Pareja, D N Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2022
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P Selenica, A Marra, N J Choudhury, et al.
The Journal of Pathology
|
June 2, 2006
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
J S Reis-Filho, C Pinheiro, M B K Lambros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
J Veeraraghavan, C De Angelis, R Mao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2013
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
A F C Okines, D Gonzalez de Castro, D Cunningham, et al.
Page
of 10